Delivery Order SPE2DB25D3306-SPE2DB25FUALQ

Award Date 1/3/25
Potential Completion Date 1/6/25
Potential Value $8.1K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $5,984.41 firm-fixed-price delivery order is for the supply of RESTASIS 0.05% eye emulsion, a specialty medication, to support military healthcare programs. The award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, which serves as a...
This federal contract award, valued at $16,992.30, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of RESTASIS 0.05% eye emulsion. The contract is a delivery order under a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., with the DLA Troop Support Medical, valued at up to $999,999,999.00 through November 2026. This IDC serves as the primary vehicle for...
This federal contract award, valued at $1,080.48, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of RESTASIS 0.05% eye emulsion. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., with the DLA Troop Support Medical. This IDC, valued at up to $999,999,999.00, serves as the primary vehicle for Amerisourcebergen to...
The federal contract award is to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, to supply the Defense Logistics Agency (DLA) with 4566582548 units of the drug RESTASIS 0.05% eye emulsion. The contract is a delivery order with a firm fixed price of $1,325.95 and a completion date of December 3, 2024. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for...
This federal contract award, valued at $56,700.31, was issued by the Defense Logistics Agency (DLA) to the prime contractor Amerisourcebergen Drug Corp. The contract, which is a Delivery Order under an Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, covers the procurement of RESTASIS 0.05% eye emulsion 60s, a specialty pharmaceutical product. The IDC, valued at $999,999,999, serves as a primary vehicle for Amerisourcebergen to provide a comprehensive range of...
This federal contract award, valued at $50,726.84, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of RESTASIS 0.05% eye emulsion, a prescription eye medication, to support federal healthcare programs. This award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support Medical, which...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $7,325.82 firm fixed-price delivery order is for the supply of Restasis 0.05% eye emulsion, a specialty medication. This award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, which serves as a primary vehicle for providing a...
This federal contract award to Amerisourcebergen Drug Corp was issued by the Defense Logistics Agency (DLA) Troop Support Medical. The $3,944.23 firm-fixed-price delivery order is for the supply of RESTASIS 0.05% eye emulsion, a prescription medication. The contract has an ultimate completion date of October 10, 2024. Amerisourcebergen, a major pharmaceutical distributor, is the prime contractor for this award, which is part of a larger Indefinite Delivery Contract (IDC) valued at up to...
This federal contract award, valued at $2,190.35, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The delivery order contract covers the supply of RESTASIS 0.05% eye emulsion, a specialty medication, to support military healthcare programs. This award is part of a larger $999,999,999 Indefinite Delivery Contract between Amerisourcebergen and the DLA Troop Support Medical, which provides a comprehensive range of pharmaceutical...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award, valued at $1,080.48, is for the delivery of RESTASIS 0.05% eye emulsion medication. This delivery order is part of a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., with the DLA Troop Support Medical division, valued at up to $999,999,999.00 and running...
  • SPE2DB25D3306
    Indefinite Delivery Contract
  • SPE2DB25D3306-SPE2DB25FUALQ
    Delivery Order

This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, was issued by the Defense Logistics Agency (DLA) for the procurement of RESTASIS 0.05% eye emulsion. The contract, valued at $8,130.05, is a delivery order under an Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical division, which serves as a comprehensive vehicle for providing a wide range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract does not have a set-aside designation, indicating open competition. This award demonstrates Amerisourcebergen's ongoing role as a key vendor for federal healthcare programs, particularly within the Department of Defense and Veterans Affairs systems, delivering essential pharmaceutical and medical commodities across various therapeutic areas.

Generated 5/21/25, 10:35 AM